Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
BRAF V600
Cancer:
Melanoma
Drug:
Keytruda (pembrolizumab)
(
PD1 inhibitor
) +
indoximod (NLG8189)
(
IDO inhibitor
)
Direction:
Sensitive
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Source:
clinicaltrials.gov
Title:
A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic Melanoma (NLG2107)
Excerpt:
...Have documentation of V600-activating BRAF mutation status or consent to BRAF V600 mutation testing during the screening period...
Trial ID:
Indigo301
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login